These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 18829568)

  • 1. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
    Yi JM; Tsai HC; Glöckner SC; Lin S; Ohm JE; Easwaran H; James CD; Costello JF; Riggins G; Eberhart CG; Laterra J; Vescovi AL; Ahuja N; Herman JG; Schuebel KE; Baylin SB
    Cancer Res; 2008 Oct; 68(19):8094-103. PubMed ID: 18829568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypomethylation regulates CD133 expression in human gliomas.
    Tabu K; Sasai K; Kimura T; Wang L; Aoyanagi E; Kohsaka S; Tanino M; Nishihara H; Tanaka S
    Cell Res; 2008 Oct; 18(10):1037-46. PubMed ID: 18679414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
    Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
    Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
    Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
    Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer.
    Pellacani D; Packer RJ; Frame FM; Oldridge EE; Berry PA; Labarthe MC; Stower MJ; Simms MS; Collins AT; Maitland NJ
    Mol Cancer; 2011 Jul; 10():94. PubMed ID: 21801380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
    Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
    Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
    Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
    Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
    Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
    Lönnroth C; Andersson M; Nordgren S; Lundholm K
    Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection.
    Sgambato A; Puglisi MA; Errico F; Rafanelli F; Boninsegna A; Rettino A; Genovese G; Coco C; Gasbarrini A; Cittadini A
    J Cell Physiol; 2010 Jul; 224(1):234-41. PubMed ID: 20333645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
    Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
    Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo.
    Gemei M; Mirabelli P; Di Noto R; Corbo C; Iaccarino A; Zamboli A; Troncone G; Galizia G; Lieto E; Del Vecchio L; Salvatore F
    Cancer; 2013 Feb; 119(4):729-38. PubMed ID: 23027178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers.
    Jeon YK; Kim SH; Choi SH; Kim KH; Yoo BC; Ku JL; Park JG
    World J Gastroenterol; 2010 Jul; 16(25):3153-60. PubMed ID: 20593500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
    Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
    Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of multidrug resistance genes in normal and cancer stem cells.
    Shervington A; Lu C
    Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
    Konduri SD; Srivenugopal KS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Foster DC; Kisiel W; Ali-Osman F; Kondraganti S; Lakka SS; Rao JS
    Oncogene; 2003 Jul; 22(29):4509-16. PubMed ID: 12881707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
    Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
    J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD133 is essential for glioblastoma stem cell maintenance.
    Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
    Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.
    Dittfeld C; Dietrich A; Peickert S; Hering S; Baumann M; Grade M; Ried T; Kunz-Schughart LA
    Radiother Oncol; 2009 Sep; 92(3):353-61. PubMed ID: 19699546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to hypoxia-induced, BNIP3-mediated cell death contributes to an increase in a CD133-positive cell population in human glioblastomas in vitro.
    Kahlert UD; Maciaczyk D; Dai F; Claus R; Firat E; Doostkam S; Bogiel T; Carro MS; Döbrössy M; Herold-Mende C; Niedermann G; Prinz M; Nikkhah G; Maciaczyk J
    J Neuropathol Exp Neurol; 2012 Dec; 71(12):1086-99. PubMed ID: 23147506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.